905. Risk of Hepatitis B Reactivation in Patients Receiving Ibrutinib: The National VA Cohort
Ting-Yi Chen(Central Texas Veterans Health Care System), Chetan Jinadatha(Texas A&M Health Science Center), John David Coppin, David Jacob(Central Texas Veterans Health Care System)
Cited by 0
Related Papers
International registry on the use of the CytoSorb® adsorber in ICU patients
|Medizinische Klinik - Intensivmedizin und Notfallmedizin|2017|116
Etoposide Quinone Is a Redox-Dependent Topoisomerase II Poison
|Biochemistry|2011|55
Diclofenac reduces the risk of Alzheimer’s disease: a pilot analysis of NSAIDs in two US veteran populations
|Therapeutic Advances in Neurological Disorders|2020|42
Hemoadsorption in the critically ill—Final results of the International CytoSorb Registry
|PLoS ONE|2022|41
Provider Attitudes Toward Risk-Based Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis in the United States
|Clinical Gastroenterology and Hepatology|2020|38